The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Allo-HSCT for elderly patients with MF: Results from the German Registry for Stem Cell Transplantation study
|
For patients with intermediate- or high-risk MF, allo-HSCT is typically recommended in patients aged <70 years.1 In recent years, an increased number of patients with MF aged ≥70 years have undergone allo-HSCT; however, data supporting allo-HSCT in these patients are limited.1 A multicenter, retrospective study using the DRST assessed the feasibility of allo-HSCT in 115 patients aged ≥70 years with MF.1 Results from this analysis were published in Transplantation and Cellular Therapy by Gagelmann et al.1 |
| Key learnings |
| The absolute number of allo-HSCT per year increased during 2007 to 2021, with a spike from 2019 onward. The HCT-CI of patients improved over time, and the proportion of patients receiving RIC increased. |
| Results suggest that allo-HSCT in patients aged ≥70 years with MF is feasible, with a 3-year OS rate of 55%. |
| The 1-year and 3-year CIR were 7% and 11%, respectively, and the 1-year and 3-year cumulative incidence of NRM were 22% and 38%, respectively. |
| The 100-day cumulative incidence of aGvHD and the cumulative incidence of cGvHD were 33% and 55%, respectively, and the 3-year estimated GRFS rate was 37%. Abbreviations: AE, adverse event; BAT, best available therapy; GI, gastrointestinal; MF, myelofibrosis; SVR35, spleen volume reduction. |
| Patients with unmutated CALR/MPL driver mutation genotype had lower survival compared with patients with CALR/MPL-mutated genotype (HR, 3.42; 95% CI, 1.01–11.60). HCT-CI and dose intensity did not impact survival. |
| This large, multicenter study demonstrated the survival benefit of allo-HSCT in patients aged ≥70 years with MF and highlights an increase in allo-HSCT rates and patient fitness in recent years. |
Abbreviations: aGvHD, acute graft-versus-host disease; allo-HSCT, allogeneic hematopoietic stem cell transplantation; cGvHD, chronic graft-versus-host disease; CI, confidence interval; CIR, cumulative incidence of relapse; DRST, German Registry for Stem Cell Transplantation; GRFS, graft-versus-host disease and relapse-free survival; HCT-CI, Hematopoietic Cell Transplantation-specific Comorbidity Index; HR, hazard ratio; MF, myelofibrosis; NRM, non-relapse mortality; OS, overall survival; RIC, reduced-intensity conditioning.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?
